Search
Research
Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic studySince 1955, the recommended strategy for rheumatic heart disease secondary prophylaxis has been benzathine penicillin G injections administered intramuscularly every 4 weeks. Due to dosing frequency, pain, and programmatic challenges, adherence is suboptimal. It has previously been demonstrated that BPG delivered subcutaneously at a standard dose is safe and tolerable and has favorable pharmacokinetics, setting the scene for improved regimens with less frequent administration.
Research
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive CardiologyThe heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present consensus document aims to provide practical evidence-based information to support the implementation of effective preventive measures.
End RHD CRE News & Events
News & Events
Rheumatic Heart Disease Endgame Strategy: what does it mean to community?Across Australia, more than 5,000 Aboriginal and Torres Strait Islander people are currently living with rheumatic heart disease (RHD) or its precursor, acute rheumatic fever (ARF).
News & Events
RHD a notifiable conditionWestern Australian doctors are now required by law to report all cases of rheumatic heart disease.
Research
Screening for rheumatic heart disease: Quality and agreement of focused cardiac ultrasound by briefly trained health workersAfter brief training, health workers with no prior experience in echocardiography can obtain adequate quality images and make a reliable assessment
Research
Controlling acute rheumatic fever and rheumatic heart disease in developing countries: Are we getting closer?Improved opportunities for the primary prevention of ARF now exist, because of point-of-care antigen tests for Streptococcus pyogenes, and clinical decision...
Research
Status of research and development of vaccines for Streptococcus pyogenesVaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development
Research
Changes in the clinical and epidemiological features of group A streptococcal bacteraemia in Australia's Northern TerritoryThis study adds to emerging data suggesting increasing importance of iGAS in low- and middle-income settings globally.
Research
Group A Streptococcus, Acute Rheumatic Fever and Rheumatic Heart Disease: Epidemiology and Clinical ConsiderationsA directed approach to the differential diagnosis of acute rheumatic fever now includes the concept of low-risk versus medium-to-high risk populations